Evaluation of 18F-FDG PET/CT SUVmax and T/MB ratio in assessing aggressiveness and predicting therapeutic efficacy in non-Hodgkin's lymphoma
10.3969/j.issn.1000-484X.2025.11.015
- VernacularTitle:18F-FDG PET/CT SUVmax、T/MB值对非霍奇金淋巴瘤侵袭性的评估及治疗效果预测
- Author:
Chuanqin ZHANG
1
;
Qi HUANG
;
Peiqing YANG
;
Zelong FENG
;
Fang LI
;
Xiaoping LI
;
Pan WANG
Author Information
1. 遵义医科大学附属医院核医学科,遵义 563000
- Publication Type:Journal Article
- Keywords:
Non-Hodgkin's lymphoma;
PET/CT;
SUVmax;
T/MB;
Ki-67
- From:
Chinese Journal of Immunology
2025;41(11):2645-2650
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate factors influencing 18F-FDG PET/CT SUVmax,T/MB ratio and Ki-67 expression in non-Hodgkin's lymphoma(NHL),to analyze their correlations with lymphoma aggressiveness and their potential advantages in predicting therapeutic efficacy.Methods:A retrospective analysis was conducted to investigate correlations between tumor SUVmax,T/MB ratio,and Ki-67 expression with NHL aggressiveness and clinical characteristics in 99 patients;whether SUVmax,T/MB ratio and Ki-67 served as independent prognostic factors influencing therapeutic efficacy was examined,and potential utility of ΔSUVmax and ΔT/MB as biomarkers for treatment response assessment were evaluated.Results:Aggressive NHL demonstrated significantly higher SUVmax,T/MB ratio and Ki-67 level compared to indolent NHL and aggressive/indolent NHL(P<0.05).A pretreatment SUVmax≥9.05,T/MB≥5.115 or Ki-67≥55%could predict clinical remission in NHL patients post-treatment,while post-treatment reductions of ΔSUVmax≥22.65%or ΔT/MB≥34.85%were associated with achieved clinical remission.Conclusion:SUVmax,T/MB ratio and Ki-67 are closely associated with aggressiveness of NHL,which can be predicted whether NHL will be relieved after treatment.ΔSUVmax and ΔT/MB can assess whether NHL has been relieved after treatment.
